leadf
logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy says four non-executive directors to step down at next month's AGM

The board of the developer of next-generation proton therapy systems for cancer treatment said its board will be reduced to eight following the departures

Advanced Oncotherapy PLC -

Advanced Oncotherapy PLC (LON:AVO) has said its board will be reduced to eight members from 12 following the resignation of four non-executive directors.

Stepping down at the company’s annual meeting next month are Gabriel Urwitz, Peter Sjöstrand, Allen Han,  and Dr Yuelong Huang.

Thanking them, chairman Dr Mike Sinclair said: “As valued board members, they have helped Advanced Oncotherapy to progress to a leading position as a technology disruptor in proton therapy, and we wish them all the best in their future endeavours.”

The slimmed-down board will consist of three executive members and five non-executive directors.

AVO is a developer of next-generation proton therapy systems for cancer treatment.

The technology is based on work by ADAM, which AVO bought in 2013 from CERN – the European particle physics lab that built the Hadron collider.

The major plus point of proton therapy is that it can pinpoint tumours more precisely, which means less damage to surrounding healthy tissues.

Proton therapy facilities have traditionally been pricey and large, requiring a space the size of a football pitch to run.

But AVO thinks it has solved that problem, and LIGHT is being built to fit in the basement of a townhouse in Harley Street, central London.

Its modular design, lighter weight and better proton efficiency also help to keep costs down, which should open proton therapy up to many more patients.

The first patient is expected to be treated at Harley Street next year.

Quick facts: Advanced Oncotherapy PLC

Price: 29.5 GBX

LSE:AVO
Market: LSE
Market Cap: £90.38 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Morning Report: Lloyds ends PPI headache; Sirius Minerals 'is quality' says...

Headlines from the Proactive UK newsroom. Anglo American (LON:AAL) has repeated that Sirius Minerals (LON:SXX) is a “quality” investment which is expected to “fit well” with the FTSE 100 group’s strategy. Anglo, which has made a bid for the firm, says the project in North Yorkshire is...

on 20/2/20

2 min read